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Think big about developing the science
The advent of big cannabis, tobacco and alcohol companies,
and interactions between them, calls for big policy
innovations that contend with major challenges to public
health. Big science is also needed, in the form of major new
investments in understanding the issues to inform societal
responses.
It is timely to consider what the legalized cannabis industry
may now do about its potential regulation and how other
addiction producers are operating in that sector. This
market expansion has been long anticipated, and indeed,
it has been planned for decades [1]. Adams and colleagues
[2] gather and examine uncomfortable early evidence for
New Zealand to demonstrate why it is appropriate to be
concerned.
The cannabis industry is not a separate actor from other
addiction industries and it is the big players who are of par-
ticular concern, not the small scale operators [3]. This is
not new. Diageo’s ongoing obligations to the thalidomide
survivors, which they continue to report to the stock mar-
ket, originated in a predecessor company getting in on
drugs [4]. Big companies are governed by the profit imper-
ative and legally mandated to maximize shareholder value
in the United States and the United Kingdom [5]. They
have extensive resources and are adept at using them to
advance their own business interests. They also possess ad-
vanced understanding of complex political systems and
how to navigate them [6]. Drug legalization debates are
weaker if they ignore the scope for large alcohol and to-
bacco companies to diversify and advance their interests
politically by infiltrating new markets, with detrimental
consequences for public health [7].
Corporatemessaginghas longexperimentedwith active
consumer and policy actor persuasion; shaping preferences
and leading opinion more broadly in market friendly
directions [8]. Growing the cannabis market presents new
opportunities for cross-marketing to develop existing
tobacco and alcohol markets and for cross-fertilisation of
political strategies. Many would agree that policy
innovations are needed, extending what is already known
about tobacco and alcohol [7], in developing the societal
responses. Recognition of the need to regulate the nascent
cannabis industry may entail more qualified endorsements
of cannabis law reform measures, for example, by
restricting the involvement of others in the addiction sector
with proven track records of major adverse consequences
for public health and society. Human rights to become
intoxicated need to be safeguarded from such corporations
if individual, community and population rights to health
are not to be undermined.
Adamsand colleagues [2] suggest that researchers have
a key role to play and cite as precedents earlier research on
other industries.We suggest there are further lessons avail-
able from this comparison. Alcohol and tobacco industry
actors have profoundly biased what we think we know
[9–11], and the implications extend to cannabis and far be-
yond. Tobacco industry research show what is possible in
influencing policy when the research is done at the scale
needed [12]. Literatures on alcohol [13] and gambling
industry [14] research, and close attention to relations
between sectors [3], are only now emerging and it shows
in public policy. Cannabis really needs more than what we
currently do as small groups of researchers “identifying,
documentingandmonitoring the risks of cannabis industry
influence” [2]. Rather than piecemeal, reactive, data
collection exercises undertaken in the margins of addiction
science or public health, what is needed are major interna-
tional research programmes that apply social sciences
discipline-based expertise proactively.We first need tomake
these topics attractive to social scientists.
Across industries it is reasonably clear what we might
be interested in, andwe need to build a convincing theoret-
ical base capable of supporting scientific advances in what
was once described as corporatology [15]. The potent
neoliberal myths propagated by the modern transnational
corporation are often quite generic in nature [8,16].
Similarities in the narratives used by the emerging global
cannabis industry and the key themes honed closely by
the tobacco and alcohol industries since the 1950s [11]
will be important to study carefully and, in the interests
of public health, to combat [12]. Empirical research on
particular industries will play key groundwork functions,
but really we need to think big in developing the science.
Maybe the corporate engineering of intoxication,
and relatedly, other subtle influences on decision-making,
is a global challenge that deserves to be more widely
recognised because the public and policy responses are
themselves subverted by the threat [17–19]. Isn’t it time
to re-imagine our research horizons?
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